Hiddo J.L. Heerspink
University Medical Center Groningen
Affiliation University Medical Center Groningen Top Publications Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019) – 6,252 citations Dapagliflozin in Patients with Chronic Kidney Disease (2020) – 5,584 citations Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention (2013) – 2,257 citations Associations of kidney disease measures with mortality and end-stage ... <a title="Hiddo J.L. Heerspink" class="read-more" href="https://journalsworld.com/researchers/hiddo-j-l-heerspink/" aria-label="Read more about Hiddo J.L. Heerspink">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
University Medical Center Groningen
Top Publications
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019) - 6,252 citations
- Dapagliflozin in Patients with Chronic Kidney Disease (2020) - 5,584 citations
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention (2013) - 2,257 citations
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis (2012) - 1,420 citations
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus (2016) - 1,381 citations
At a glance
- Full name
- Hiddo J.L. Heerspink
- ORCID
- 0000-0002-3126-3730
- OpenAlex ID
- https://openalex.org/A5031624913
Research interests
- Chronic Kidney Disease and Diabetes, Diabetes Treatment and Management, Acute Kidney Injury Research, Heart Failure Treatment and Management, Renal Diseases and Glomerulopathies
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy ↗2019 · New England Journal of Medicine6,252OpenAlex citations
- Dapagliflozin in Patients with Chronic Kidney Disease ↗2020 · New England Journal of Medicine5,584OpenAlex citations
- 2,257OpenAlex citations
- 1,420OpenAlex citations
- 1,381OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy ↗2019 · New England Journal of Medicine
- Dapagliflozin in Patients with Chronic Kidney Disease ↗2020 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 21:46:13
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.